

产品名称：TH588
产品别名：TH588

生物活性:

| | | | | | |
|---------------------------|--|--|-----------|------------|------------|
| Description | TH588 is first-in-class nudix hydrolase family inhibitor that potently and selectively engage and inhibit the MTH1 (IC ₅₀ = 5 nM). | | | | |
| IC ₅₀ & Target | IC50: 5 nM (MTH1)[1] | | | | |
| In Vitro | TH588 (2-10µM; 7-10 days) selectively and effectively kills U2OS, HeLa, MDA-MB-231, MCF-7, SW480, and SW620 cells with IC50s of 1.38, 0.83, 1.03, 1.08, 1.72, 0.8 µM[1]. | | | | |
| | Cell Viability Assay[1] | | | | |
| | Cell Line: | U2OS, HeLa, MDA-MB-231, MCF-7, SW480, SW620, VH10, HDFn cells | | | |
| | Concentration: | 2, 4, 6, 8, 10 µM | | | |
| | Incubation Time: | 7-10 days | | | |
| In Vivo | Result: | Selectively and effectively killed U2OS, HeLa, MDA-MB-231, MCF-7, SW480, and SW620 cells with IC ₅₀ s of 1.38, 0.83, 1.03, 1.08, 1.72, 0.8 µM, but was less toxic to several primary or immortalized cells. | | | |
| | TH588 (30 mg/kg; s.c.; once daily for 35 days) reduces tumour growth in SW480 xenograft cancer model[1]. | | | | |
| | Animal Model: | 5-6 weeks female SCID mice (SW480 xenograft cancer model)[1] | | | |
| | Dosage: | 30 mg/kg | | | |
| | Administration: | Subcutaneous injection; once daily for 35 days | | | |
| Solvent&Solubility | Result: | Reduced tumour growth in SW480 xenograft cancer model. | | | |
| | In Vitro: | | | | |
| | DMSO : 16 mg/mL (54.21 mM; Need ultrasonic and warming) | | | | |
| | Preparing Stock Solutions | <div>SolventMassConcentration</div> | 1 mg | 5 mg | 10 mg |
| | | 1 mM | 3.3879 mL | 16.9394 mL | 33.8788 mL |
| | | 5 mM | 0.6776 mL | 3.3879 mL | 6.7758 mL |
| | | 10 mM | 0.3388 mL | 1.6939 mL | 3.3879 mL |
| | <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。</p> <p>In Vivo:</p> <p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (8.47 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (8.47 mM，饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 µL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 µL PEG300 中，混合均匀。</p> | | | | |

| | |
|------------|---|
| | <p>向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2. 请依序添加每种溶剂： 10% DMSO \rightarrow 90% (20% SBE-β-CD in saline) Solubility: \geq 2.5 mg/mL (8.47 mM); Clear solution</p> <p>此方案可获得 \geq 2.5 mg/mL (8.47 mM，饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3. 请依序添加每种溶剂： 10% DMSO \rightarrow 90% corn oil Solubility: \geq 2.5 mg/mL (8.47 mM); Clear solution</p> <p>此方案可获得 \geq 2.5 mg/mL (8.47 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p> |
| References | <p>[1]. Gad H, et al. MTH1 inhibition eradicates cancer by preventing sanitation of the dNTP pool. <u>Nature</u>. 2014 Apr 10;508(7495):215-21.</p> |

源叶生物